Effects of tamoxifen-loaded solid lipid nanoparticles on the estrogen receptor-α (ER-α) and vascular endothelial growth factor-A (VEGF-A) genes expression in the endometrial tissue of ovariectomized female Sprague-Dawley rats

- An in vivo study was carried out to study the effect of tamoxifen-loaded solid lipid nanoparticles on the ER-α and VEGF-A genes expression.
- Tamoxifen-loaded SLN significantly reduced the mRNA levels of ERα and VEGF-A gene and the total oxidant status
- Encapsulation of tamoxifen in solid lipid nanoparticles may have less adverse effects on the oxidative stress status and incidence of endometrial cancer.

BackgroundThe effect of tamoxifen on endometrial carcinogenesis stems from its estrogen agonist effect. An in vivo study was carried out to compare the effect of tamoxifen-loaded solid lipid nanoparticles and free drug on the ER-α and VEGF-A genes expression.Material and methodsTwenty-four female Sprague-Dawley rats divided into 4 groups of six rats were used for this study. The first and second groups were ovariectomized and given tamoxifen and tamoxifen-loaded SLN respectively for six days continuously. Group 3 served as the untreated ovariectomized control group and group 4 was made up of untreated normal healthy rats. At the end of the study, the rats were sacrificed and study of the genes expression and serum oxidative stress were carried out.ResultsThe results of this study showed that treatment with tamoxifen-loaded SLN significantly reduced the mRNA levels of ERα and VEGF-A gene and the total oxidant status compared to the ovariectomized control group.ConclusionsThe results of this study revealed that encapsulation of tamoxifen in solid lipid nanoparticles may have less adverse effects on the oxidative stress status and incidence of endometrial cancer.